

## Overview

### Useful For

Aid in the diagnosis and treatment of liver, bone, intestinal, and parathyroid diseases

Determining the tissue source of increased alkaline phosphatase (ALP) activity in serum

Differentiating between liver and bone sources of elevated ALP

### Method Name

Only orderable as part of a profile. For more information see ALKP / Alkaline Phosphatase, Total and Isoenzymes, Serum.

Electrophoresis

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Specimen Required

Only orderable as part of a profile. For more information see ALKP / Alkaline Phosphatase, Total and Isoenzymes, Serum.

#### Patient Preparation:

**Fasting: 8 hours, required**

**Supplies:** Sarstedt Aliquot Tube, 5 mL (T914)

#### Collection Container/Tube:

**Preferred:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL

#### Collection Instructions:

1. Within 2 hours of collection, centrifuge the specimen.
2. For red top tubes, immediately aliquot into a plastic vial.
3. For serum gel tubes, serum may sit on gel refrigerated but must be aliquoted within 7 days.

### Specimen Minimum Volume

0.5 mL

**Reject Due To**

Gross hemolysis	Reject
Gross lipemia	OK
Gross icterus	Reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum	Frozen (preferred)	14 days	
	Ambient	7 days	
	Refrigerated	7 days	

**Clinical & Interpretive**
**Clinical Information**

Alkaline phosphatase (ALP) is present in a number of tissues including liver, bone, intestine, and placenta. The activity of ALP found in serum is a composite of isoenzymes from those sites. Serum ALP is of interest in the diagnosis of hepatobiliary disease and bone disease associated with increased osteoblastic activity.

A rise in liver ALP activity occurs with all forms of cholestasis, particularly with obstructive jaundice.

Bone ALP is elevated in disorders of the skeletal system that involve osteoblast hyperactivity and bone remodeling, such as Paget disease, rickets, osteomalacia, fractures, and malignant tumors.

Moderate elevation ALP may be seen in other disorders such as Hodgkin disease, congestive heart failure, ulcerative colitis, regional enteritis, and intra-abdominal bacterial infections.

**Reference Values**

Only orderable as part of a profile. For more information see ALKP / Alkaline Phosphatase, Total and Isoenzymes, Serum.

Ages:

< or =17 years: Reference values have not been established for patients younger than 18 years.

> or =18 years:

Liver %: 30.2-74.7

Liver U/L: 15.8-71.9

Bone %: 23.8-68.3

Bone U/L: 12.0-56.7

Intestine %: <=22.5

Intestine U/L: <=12.6

**Interpretation**

Liver alkaline phosphatase (ALP) isoenzyme is most frequently elevated when total ALP is elevated. Increased liver ALP is

associated with a wide group of conditions including acute hepatitis, cirrhosis, fatty liver, drug induced liver disease, obstruction of biliary flow, bile duct stricture, primary biliary cirrhosis and metastatic carcinoma of the liver.

Bone ALP is elevated due to increased osteoblastic activity. Abnormally elevated bone ALP may be indicative of bone tumors, Paget disease or renal rickets.

Intestinal ALP is detectable in approximately 20% of samples tested. Intestinal ALP is most frequently noted postprandially in patients with blood group O or B.

Transient hyperphosphatasemia is a temporary condition in children under 5 years, in which serum ALP activity is elevated 3-20 times the upper reference range with no clinical indications for the elevation.

Transient hyperphosphatasemia of infancy and early childhood is characterized by a marked elevation of serum alkaline phosphatase in the absence of detectable liver or bone disease, with a return to normal levels within weeks or months.

## Cautions

High concentrations of phosphate, oxalate, citrate and cyanide will inhibit alkaline phosphatase (ALP) activity.

Excess glycine may inhibit ALP activity by complexing magnesium.

Patients should be fasting. Patients may have an elevated Intestinal ALP about two hours after a fatty meal.

## Clinical Reference

1. Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics 6th ed. Elsevier; 2018
2. Lowe D, Sanvictores T, John S. Alkaline phosphatase. In: StatPearls [Internet]. StatPearls Publishing; 2021. Updated October 29, 2023. Accessed April 22, 2025. Available at [www.ncbi.nlm.nih.gov/books/NBK459201](http://www.ncbi.nlm.nih.gov/books/NBK459201)
3. Teitelbaum JE, Laskowski A, Barrows FP. Benign transient hyperphosphatasemia in infants and children: a prospective cohort. J Pediatr Endocrinol Metab. 2011;24(5-6):351-353
4. Jassam NJ, Horner J, Marzo-Ortega H, Sinclair M, Barth JH. Transient rise in alkaline phosphatase activity in adults. BMJ Case Rep. 2009;2009:bcr09.2009.2250
5. Verma J, Gorard DA. Persistently elevated alkaline phosphatase. BMJ Case Rep. 2012;2012:bcr2012006768
6. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014;29(3):269-278

## Performance

### Method Description

Alkaline phosphatase isoenzymes are separated by agarose gel electrophoresis and visualized using BCIP (5-Bromo-4-chloro-3-indolyl phosphate p-toluidine salt) substrate. (Package insert: SPIFE Touch Alkaline Phosphatase [ALP] Isoenzyme. Helena Laboratories; 01/2024)

### PDF Report

No

**Day(s) Performed**

Tuesday through Saturday

**Report Available**

3 to 5 days

**Specimen Retention Time**

7 days

**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

**CPT Code Information**

84080

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
ALPI	Alkaline Phosphatase Isoenzymes, S	12805-8

Result ID	Test Result Name	Result LOINC® Value
622367	Alkaline Phosphatase Isoenzymes, S	12805-8
622369	Liver Percent	15015-1
622368	Liver	1779-8
622371	Bone Percent	15013-6
622370	Bone	1777-2
622373	Intestine Percent	15014-4
622372	Intestine	1778-0